FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021485239> ?p ?o ?g. }

• W2021485239 endingPage "257" @default.
• W2021485239 startingPage "257" @default.
• W2021485239 abstract "Background: Cytomegalovirus (CMV) retinitis is the most common intraocular infection in patients with the acquired immunodeficiency syndrome (AIDS). If left untreated, it may lead to progressive destruction of retinal tissue and blindness. Cidofovir is a nucleotide analogue of cytosine that has potent, prolonged in vitro and in vivo activity against herpesviruses, including many CMV isolates that are resistant to ganciclovir and foscarnet. Objective: To determine whether intravenous cidofovir delays progression of previously untreated CMV retinitis. Design: Randomized, controlled trial comparing immediate with deferred cidofovir treatment. Patients in the deferred treatment group were eligible to receive cidofovir after progression of CMV retinitis was documented by retinal photography. Setting: Eight academic medical centers and an independent center that read retinal photographs. Patients: 48 patients with AIDS and previously untreated peripheral CMV retinitis who were randomly assigned to immediate (n = 25) or deferred treatment (n = 23). Intervention: Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 weeks and then once every other week. To minimize nephrotoxicity, oral probenecid and intravenous hydration with normal saline were administered with each cidofovir infusion. Measurements: Progression of CMV retinitis was assessed by bilateral, full-field retinal photographs that were read by an ophthalmologist who was masked to treatment assignment. Incidence of side effects, changes in visual acuity, effect on CMV shedding in urine and blood, and mortality were also assessed. Results: The median time to progression of CMV retinitis was 22 days (95% CI, 10 to 27 days) in the deferred treatment group and 120 days (CI, 40 to 134 days) in the immediate treatment group (P < 0.001). Neutropenia (15%) and proteinuria (12%), both asymptomatic, were the most common serious adverse events considered to be possibly related to cidofovir. Cidofovir treatment was discontinued in 10 of 41 patients (24%) because of protocol-defined treatment-limiting nephrotoxicity. Transient reactions to probenecid, including mild to moderate constitutional symptoms or nausea, occurred in 23 of 41 patients (56%) and were dose limiting in 3 (7%). Conclusions: Cidofovir was efficacious in delaying progression of previously untreated CMV retinitis. Treatment was associated with manageable side effects; strict adherence to monitoring of renal function before cidofovir was administered and concomitant administration of probenecid and saline hydration appeared to minimize drug-related nephrotoxicity." @default.
• W2021485239 created "2016-06-24" @default.
• W2021485239 creator A5002159325 @default.
• W2021485239 creator A5002429484 @default.
• W2021485239 creator A5002916327 @default.
• W2021485239 creator A5022183607 @default.
• W2021485239 creator A5025854075 @default.
• W2021485239 creator A5031577547 @default.
• W2021485239 creator A5041417402 @default.
• W2021485239 creator A5048224604 @default.
• W2021485239 creator A5049805375 @default.
• W2021485239 creator A5070228239 @default.
• W2021485239 date "1997-02-15" @default.
• W2021485239 modified "2023-10-15" @default.
• W2021485239 title "Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS" @default.
• W2021485239 doi "https://doi.org/10.7326/0003-4819-126-4-199702150-00001" @default.
• W2021485239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9036797" @default.
• W2021485239 hasPublicationYear "1997" @default.
• W2021485239 type Work @default.
• W2021485239 sameAs 2021485239 @default.
• W2021485239 citedByCount "331" @default.
• W2021485239 countsByYear W20214852392012 @default.
• W2021485239 countsByYear W20214852392013 @default.
• W2021485239 countsByYear W20214852392014 @default.
• W2021485239 countsByYear W20214852392015 @default.
• W2021485239 countsByYear W20214852392016 @default.
• W2021485239 countsByYear W20214852392017 @default.
• W2021485239 countsByYear W20214852392018 @default.
• W2021485239 countsByYear W20214852392019 @default.
• W2021485239 countsByYear W20214852392020 @default.
• W2021485239 countsByYear W20214852392021 @default.
• W2021485239 countsByYear W20214852392022 @default.
• W2021485239 countsByYear W20214852392023 @default.
• W2021485239 crossrefType "journal-article" @default.
• W2021485239 hasAuthorship W2021485239A5002159325 @default.
• W2021485239 hasAuthorship W2021485239A5002429484 @default.
• W2021485239 hasAuthorship W2021485239A5002916327 @default.
• W2021485239 hasAuthorship W2021485239A5022183607 @default.
• W2021485239 hasAuthorship W2021485239A5025854075 @default.
• W2021485239 hasAuthorship W2021485239A5031577547 @default.
• W2021485239 hasAuthorship W2021485239A5041417402 @default.
• W2021485239 hasAuthorship W2021485239A5048224604 @default.
• W2021485239 hasAuthorship W2021485239A5049805375 @default.
• W2021485239 hasAuthorship W2021485239A5070228239 @default.
• W2021485239 hasConcept C141071460 @default.
• W2021485239 hasConcept C203014093 @default.
• W2021485239 hasConcept C2522874641 @default.
• W2021485239 hasConcept C2776724271 @default.
• W2021485239 hasConcept C2776824251 @default.
• W2021485239 hasConcept C2777016524 @default.
• W2021485239 hasConcept C2777324356 @default.
• W2021485239 hasConcept C2777965375 @default.
• W2021485239 hasConcept C2779820661 @default.
• W2021485239 hasConcept C71924100 @default.
• W2021485239 hasConcept C90924648 @default.
• W2021485239 hasConceptScore W2021485239C141071460 @default.
• W2021485239 hasConceptScore W2021485239C203014093 @default.
• W2021485239 hasConceptScore W2021485239C2522874641 @default.
• W2021485239 hasConceptScore W2021485239C2776724271 @default.
• W2021485239 hasConceptScore W2021485239C2776824251 @default.
• W2021485239 hasConceptScore W2021485239C2777016524 @default.
• W2021485239 hasConceptScore W2021485239C2777324356 @default.
• W2021485239 hasConceptScore W2021485239C2777965375 @default.
• W2021485239 hasConceptScore W2021485239C2779820661 @default.
• W2021485239 hasConceptScore W2021485239C71924100 @default.
• W2021485239 hasConceptScore W2021485239C90924648 @default.
• W2021485239 hasIssue "4" @default.
• W2021485239 hasLocation W20214852391 @default.
• W2021485239 hasLocation W20214852392 @default.
• W2021485239 hasOpenAccess W2021485239 @default.
• W2021485239 hasPrimaryLocation W20214852391 @default.
• W2021485239 hasRelatedWork W1979471217 @default.
• W2021485239 hasRelatedWork W1998817680 @default.
• W2021485239 hasRelatedWork W2008736461 @default.
• W2021485239 hasRelatedWork W2081755907 @default.
• W2021485239 hasRelatedWork W2142455206 @default.
• W2021485239 hasRelatedWork W2145821687 @default.
• W2021485239 hasRelatedWork W2408604974 @default.
• W2021485239 hasRelatedWork W2410417504 @default.
• W2021485239 hasRelatedWork W2411361522 @default.
• W2021485239 hasRelatedWork W2418784502 @default.
• W2021485239 hasVolume "126" @default.
• W2021485239 isParatext "false" @default.
• W2021485239 isRetracted "false" @default.
• W2021485239 magId "2021485239" @default.
• W2021485239 workType "article" @default.